Editing inside the body: an early ATTR amyloidosis study

What the research found

Gillmore and colleagues reported early results from six patients with hereditary transthyretin amyloidosis and polyneuropathy. The investigational treatment used lipid nanoparticles to deliver CRISPR components aimed at reducing transthyretin production. The report showed dose-dependent reductions in circulating TTR over the initial observation period, providing evidence of target engagement inside the body.

Where the evidence stops

The initial study was small and its early results did not establish long-term clinical benefit or all possible harms. Lowering a target protein is different from demonstrating durable improvement in disease.

The private-client perspective

A precision programme should connect each intervention to a defined causal pathway and monitor both benefit and safety over time. For clients, the questions include who remains responsible for follow-up, how unexpected effects are handled and whether standard alternatives exist. The appeal of a one-time intervention should never obscure the possibility of a long-lasting biological effect.

Read the source

1. CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis. (2021-06-26)

An independent editorial synthesis of published research, not an original NoahThera study or a personal medical recommendation. Evidence stages are identified above; cited researchers and institutions are not represented as NoahThera partners.